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REVIEW
Abstract: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder which
causes deforming joint disease and a spectrum of extraarticular manifestations. Poor disease
control may lead to functional impairment and loss of independence. In recent times a prominent
role for B cells in the pathogenesis of RA has been suggested. Two major theories have been
postulated to explain the role of rheumatoid factor (RF) in the RA inflammatory process and
the reason for RF overproduction; the loss of tolerance model and the autonomous mutated B
cell model. With this in mind, strategies have been adopted to deplete B cells including the
use of the anti-CD20 antibody rituximab. Rituximab leads to complement mediated lysis of B
cells as well as antibody-dependant cellular cytotoxicity. It has been hypothesized that
rituximab may also initiate apoptosis in RA and alter the ability of B cells to respond to
antigen and other stimuli. Several recent studies using rituximab have demonstrated significant
declines in RA activity providing evidence for the role of B cells in RA. Rituximab would
appear to be a major addition to the increasing therapeutic options for sufferers of RA.
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Introduction
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder with
consequences extending well beyond the recognizable joint disease. Poor disease
control leads to pain and deformity with consequent functional impairment and loss
of independence. The RA sufferer may also experience significant systemic illness
due to extraarticular disease which includes nodules, vasculitis, pulmonary fibrosis,
nerve entrapment, and myelopathy due cervical disease (Lee and Weinblatt 2001).
The RA syndrome and, in particular, extraarticular disease is associated with the
production of the autoantibody known as rheumatoid factor (RF). This is an antibody
directed against the Fc portion of immunoglobin G (IgG) constant regions (Edwards
and Cambridge 1998). RF is found in 80% of patients with RA, but also may be
found in normal individuals.
Several biological therapeutic approaches have been introduced for use typically
in patients refractory to conventional agents such as methotrexate. These include
tumor necrosis factor-α (TNF-α) and interleukin (IL)-1 receptor antagonists in an
attempt to block the well described inflammatory cytokine pathways present in the
disease (Choy and Panayi 2001). A more prominent role for B cells in the pathogenesis
of RA has been suggested in recent times (Edwards and Cambridge 1995). With this
in mind, strategies have been adopted to deplete B cells including the use of the anti-
CD20 antibody, rituximab. Several recent studies using rituximab have demonstrated
significant declines in RA activity providing evidence for the role of B cells in RA.
In this review we provide an overview of the rationale for and experience with
rituximab in RA.
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Pathogenesis of RA
Current theories of the aetiopathogenesis of RA suggest that
the disease is due to a combination of synovial hyperplasia
and an inflammatory cell infiltrate secreting cytokines
leading to joint destruction and deformity (Lee and Weinblatt
2001). Cytokines are believed to play a major role in the
pathogenesis of the disease (Choy and Panayi 2001) and
interact at various levels as outlined in schematic form in
Figure 1. Tumor necrosis factor-α has often been considered
to be the central cytokine responsible for the inflammatory
infiltrate, particularly as one of the major cell populations
in the rheumatoid joint is the macrophage. Feldmann et al
(1996) and Firestein et al (1990) demonstrated in synovial
cultures that TNF-α protein and mRNA expression were
high in the macrophage population of RA patients compared
with normal. In addition, inhibition of synovial TNF-α
expression with TNF-α antibodies resulted in suppression
of not only TNF-α but other inflammatory cytokines such
as IL-1, IL-6, IL-8 and granulocyte-macrophage colony-
stimulating factor (GMCSF) (Brennan et al 1989).
A natural progression of this work was to assess the role
of anti-TNF-α−antibodies in clinical trials involving patients
with RA. Recent trials using synthetic TNF-α antibodies
have resulted in substantial remissions in RA patients
compared with methotrexate or placebo reinforcing the in-
vitro and animal data (Maini et al 1999; Weinblatt et al 1999).
Where available, these anti-TNF-α−antibodies are now
considered standard of care in RA for patients that have
failed methotrexate or other disease-modifying anti-
rheumatic drugs (DMARDs).
Some proponents of a role for T cells in RA point to the
evidence for a genetic component in the disease.
Approximately 80% of RA patients express human
leukocyte antigen (HLA) DRB1 0404, 0401 subtypes
compared with 28% in the general population (Lanchbury
1992). Given that the main function of HLA Class II
molecules is to present antigen to CD4, it is a proposed that
an inflammatory cascade is initiated through co-stimulatory
molecules (Fox 1997). It is possible that secretion of
interferon gamma from these activated T cells may activate
macrophages to produce TNF-α. However, anti-CD4
antibody therapy was not beneficial in a randomised trial
suggesting that T cells are not central to the pathogenesis of
RA (van der Lubbe et al 1997). In contrast inhibition of co-
stimulatory molecules such as CTLA-4Ig was recently
successful (Kremer et al 2005) in ameliorating disease
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Figure 1 Proposed pathways in the inflammatory cascade of rheumatoid arthritis. Rituximab would be expected to act on B cells and RF production, thus decreasing
TNF-α production by macrophages via Fc receptor binding.
Abbreviations: APC, antigen-presenting cell; IL, interleukin; INFγ, interferonγ; HLA-DR, human leukocyte antigen DR; PMN, polymorphonuclear cell; RF, rheumatoid
factor; TNFα, tumor necrosis factor-α.Therapeutics and Clinical Risk Management 2006:2(2) 209
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pointing to activation of T cells as a target for therapy in
RA.
Rationale for treatment with
rituximab (the role of B cells in
RA)
Although T cell and macrophage populations dominate the
current theories of pathogenesis of RA, there is emerging
evidence that B cells and their production of RF may also
be intrinsic to RA (Mitchison et al 2000). The possibility
that RF is implicated in disease pathogenesis is raised by
the consistent finding that 80% of patients with RA have
elevated serum levels of the autoantibody which correlates
with disease severity and extra-articular manifestations
(Edwards et al 1999).
Rheumatoid factor is an antibody directed against the
Fc fragment of the IgG molecule (Sutton et al 2000). In
RA, RF can be of all subclasses, but is chiefly an IgG
antibody that has a high affinity to receptors on macrophages
and neutrophils, fixes complement, and can migrate into
the extravascular space. RF in RA patients also shows a
high degree of substitution mutations indicating affinity
maturation (Randen et al 1993). This suggests that RF in
RA patients is produced in response to an antigen/T cell-
driven process of somatic mutation of the immunoglobulin
gene sequence. In contrast, the RF produced by normal
individuals in response to infection or immunization is
usually IgM, transient, with low affinity, and of germ line
origin suggesting it is part of the innate immune response
(Thompson et al 1995). Given that RF is different in RA
patients, it has been important to discover how it would
contribute to inflammation and persist in patients with RA.
There are two major theories that have been postulated
to explain the role of RF in the RA inflammatory process
and the reason for RF overproduction: i) The loss of
tolerance model due to CD40–CD40L activation signals
(Kyburz et al 1999); ii) The autonomous mutated B cell
model (Edwards et al 1999).
The loss of tolerance model due to
CD40–CD40L activation signals
B cells can act as antigen-presenting cells. After engulfing
foreign material they present antigen fragments to T cells
in association with Major Histocompatibility Complex
(MHC) class II. CD40 and CD40L are co-stimulatory
molecules essential to the antigen-presenting role of B cells,
particularly in RA (Sekine et al 1998). On engagement of T
and B cells, the T cell becomes activated and expresses
CD40L, which in turn binds CD40 on the B cell, initiating
the process of somatic hypermutation of the immunoglobulin
gene and class switching. In follicular centres of lymph
nodes, antigen complexed with the C3d complement
fragment can also signal to the B cell to proliferate without
the assistance of T cells. In the case of a self-antigen,
tolerance is generally initiated. This may be either by a lack
of co-stimulation by the CD40–CD40L system or changed
specificity of the B cell. Provision of either of these signals
leads to apoptosis of the B cell.
Kyburz et al (1999) conducted experiments in a
transgenic animal model suggesting overactivity of the
CD40–CD40L system may occur in RA (Kyburz et al 1999).
This overactivity results in excess IL-4 production, leading
to the inhibition of B cell apoptosis. There is also
differentiation of B cells into plasma cells, thus maintaining
them in germinal centres in a state of continuous RF
production. CD40 is expressed on synovial monocytes,
which potentially leads to TNF-α production. CD40 is also
found on synovial fibroblasts which may provide a
supportive stroma for B cell differentiation within the joint
(van Kooten and Banchereau 2000). CD40L is expressed
on activated T cells within the lymphoid aggregates of joints
in RA patients (Sekine et al 1998). This theory does not
explain the actual role of RF, but can account for the
activation signals that potentiate its production.
The autonomous mutated B cell model
Edwards and Cambridge (1998) have promoted a hypothesis
that RF itself is pathogenic due to a random immunoglobulin
gene mutation leading to dysfunctional IgG which initiates
inflammation by Fc receptor attachment, TNF-α production
and complement activation. This hypothesis predicts that B
cell production of IgG RF arises due to a random mutation
when immunoglobulin gene rearrangement occurs in the
germinal centre upon antigen stimulation (Pulendran et al
1997). If the antigen is a protein involved in the immune
system (such as IgG) it is possible that RF-producing B cells
will undergo apoptosis as part of tolerance or may escape
tolerance leading to autonomous production such as in RA
(Edwards and Cambridge 1995). Once RF is produced by a
clone of B cells which have escaped tolerance, it is likely
that because it is an IgG immunoglobulin, it has the ability
to pass out of the circulation and attach to the IgG Fc receptor
on macrophages in the synovium. The FcγRIIIa receptor is
abundantly expressed on synovial macrophages (Edwards,
Blades, et al 1997) and when activated by dimers of IgG,Therapeutics and Clinical Risk Management 2006:2(2) 210
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such as RF, it facilitates the release of TNF-α (Abrahams et
al 2000). TNF-α in turn upregulates the expression of
vascular cell adhesion molecule (VCAM) and other
adhesion molecules (Edwards, Leigh, et al 1997), promoting
survival of B cells in intimate contact with the macrophages.
‘Nurse-like’ cells in bone marrow and synovium in RA
patients are also likely to contribute to prolonged survival
and IgG production via upregulation of VCAM and
intercellular adhesion molecule (ICAM) (Shimaoka et al
1998). The dimerization of RF IgG molecules can also
activate complement which will contribute to the
inflammatory cell infiltrate in the pannus (Edwards and
Cambridge 1998b).
Thus it is clear that B cells can be pathogenic in RA at
numerous levels. B cells are the source of both RF and IL-
6 thus potentiating their own secretion of autoantibody.
These pathways can interact with the production of TNF-α
via the Fc portion of macrophages (Abrahams et al 2000).
In addition, the B cell’s ability to act as an antigen-presenting
cell initiates the CD40–CD40L cascade and the T cell
cytokine cascade. The availability of rituximab provides an
attractive therapeutic option to deplete B cells in RA and
thus disrupt these pro-inflammatory pathways which are
central to the pathogenesis of RA.
Clinical trials using rituximab in
RA
Rituximab is a mouse–human chimeric monoclonal antibody
that has a murine variable region that is specific for CD20,
an antigen found on the surface of B cells in their earlier
stages of development prior to the plasma cell stage. The
IgG1 heavy and light chain constant regions are human.
CD20 is also found on most malignant B cell lymphoma
cells and is postulated to be involved in regulation of the
cell cycle and cell differentiation. Rituximab leads to
complement-mediated lysis of B cells as well as antibody-
dependant cellular cytotoxicity. It has been hypothesized
that rituximab may also initiate apoptosis in RA and alter
the ability of B cells to respond to antigen and other stimuli
(Tsokos 2004). This agent was originally introduced in 1997
for the treatment of low grade lymphoma alongside
combined chemotherapy. There has since been a
proliferation of potential indications for its use including
an extended spectrum of hematological malignancies,
nonmalignant hematological disease such as immune
thrombocytopenic purpura (ITP), autoimmune hemolytic
anemia, and other autoimmune diseases. There is now
considerable experience in rituximab use, with the agent
being generally well tolerated. The main problems with its
use include infusional reactions, cytopenias, and
immunosuppression. It is probable that the lack of depletion
of plasma cells with rituximab has avoided significant
immunoglobulin deficiency in most clinical trials including
rheumatoid patients (Edwards et al 2004; Moore et al 2004).
CD20 is not expressed on hematopoietic stem cells and
for this reason B cells may be depleted by rituximab without
preventing their regeneration whilst hopefully eliminating
the RF-producing clone. Rituximab has been used to date
in patients that have been heavily pre-treated with more
conventional agents. It has generally been combined in use
with other agents, most commonly cyclophosphamide and
methotrexate.
In the first published data by Edwards and Cambridge
(2001), rituximab was used in combination with
cyclophosphamide in 5 patients leading to an American
College of Rheumatology (ACR)50 in 5/5 and ACR70 in 3/
5 at 26 weeks. This was followed by other studies by
Leandro et al (2002), De Vita et al (2002), Kneitz et al
(2004), and Higashida et al (2005) demonstrating efficacy
of rituximab (see Table 1). Leandro et al (2002) studied the
use of rituximab alone compared with rituximab and
differing combinations of cyclophosphamide and
methotrexate in five different cohorts. The results of this
study suggested that rituximab alone may not be as effective
and that cyclophosphamide or methotrexate would be
required to provide activity on non-B cell populations.
Cyclophosphamide may confer a currently unexplained
synergistic action with rituximab that may be important in
the mechanism of the response. In addition to its B cell
depleting properties, cyclophosphamide may have other
Table 1 Major clinical trials reporting rituximab use in
rheumatoid arthritis
Trial Number ACR50 at
of patients 6 months (%)
Edwards and Cambridge 2001 5 100
De Vita et al 2002 5 40
Leandro et al 2002 291 59
Moore et al 2004 10 80
Edwards et al 2004 161  42
2
Higashida et al 2005 17 33
Note: Kneitz et al 2004 reported a significant improvement in disease activity
score at 28 weeks (>1.2) in 4/5 patients (ACR50 not reported); 
122 patients
underwent 29 courses; 
242% of 81 patients receiving rituximab combined with
cyclophosphamide or methotrexate
Abbreviations: ACR, American College of Rheumatology. Therapeutics and Clinical Risk Management 2006:2(2) 211
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immunosuppressive properties, such as an effect on T cell
co-stimulation as has been demonstrated in systemic lupus
erythematosus (SLE) patients (Amano et al 2000). We tested
the hypothesis that cyclophosphamide was a key contributor
to the effect of rituximab in a trial of patients who had
previously received cyclophosphamide a median of 25
months earlier as part of hemopoietic stem cell transplant
(HSCT) treatment (Moore et al 2002). During the HSCT
trial, it was demonstrated that the major responses to HSCT
was during the period of B cell lymphopenia (months 3–9).
Similarly, the use of rituximab in the same cohort of patients
produced the same pattern of B cell depletion and response
during the 3–9 month period (Moore et al 2004). These
heavily pre-treated patients did not demonstrate major
toxicity from rituximab and importantly 9/10 did not
experience hypogammaglobulinemia.
Edwards followed up his pioneering work with a much
larger series of 161 patients in the only published
randomized study using rituximab in RA (Edwards et al
2004). Patients all had active RA despite treatment with
methotrexate and were treated in 4 groups; methotrexate
alone, rituximab, rituximab plus cyclophosphamide (750 mg
on days 3 and 17), or rituximab plus methotrexate. In the
three rituximab groups the dose was a 1000 mg intravenous
infusion on days 1 and 15. At 24 weeks ACR50 was achieved
in 43% with the rituximab–methotrexate combination and
41% in the rituximab–cyclophosphamide combination. This
was significantly better than the 13% in methotrexate alone
(p=0.005). Responses were also noted in the rituximab alone
arm but were inferior to that achieved in the combinations
arms.
Concluding Remarks
Thus the trials outlined in Table 1 clearly signify the
importance of the B cell in the immunopathogenesis of RA.
Edwards et al (2004) and our own data point more to the
importance of RF eradication which is reliant on and
naturally follows B cell depletion. Future work will need to
assess the optimal dosing schedule to obtain RF eradication
and studies are currently underway and only reported in
abstract form.
The data with rituximab in RA is equivalent to and
perhaps even superior to some of the published TNF-α
antagonist trials (Maini et al 1999; Weinblatt et al 1999)
where ACR50 rates at 6 months ranged between 26%–39%.
In addition, Abatacept, a newer constimulator modulator
has recently been reported to have a similar response rate
(Kremer et al 2005). The major advantages of rituximab
over these agents would appear to be the shorter dosage
schedule, which avoids the need for regular hospital visits.
Another potential advantage is less infection due to the
sparing of immunoglobulin deficiency, although a longer
follow up will be required to confirm this observation.
Further studies are required at this stage to assess infection
rate and optimal dosage scheduling, but rituximab would
appear to be a major addition to the increasing therapeutic
options for sufferers of this debilitating disease.
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